Quick Answer
BIOCRYST PHARMACEUTICALS INC reported Diluted EPS of $1.21 per share for fiscal year 2025.
BIOCRYST PHARMACEUTICALS INC Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $1.21 | +381.4% |
| 2024 | -$0.43 | +63.6% |
| 2023 | -$1.18 | +11.3% |
| 2022 | -$1.33 | -29.1% |
| 2021 | -$1.03 | +5.5% |
| 2020 | -$1.09 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.06 | +185.7% | +200.0% |
| June 30, 2025 | $0.02 | +133.3% | — |
| March 31, 2025 | $0.00 | +100.0% | +100.0% |
| September 30, 2024 | -$0.07 | +63.2% | -16.7% |
| June 30, 2024 | -$0.06 | +85.0% | +64.7% |
| March 31, 2024 | -$0.17 | +39.3% | +10.5% |
| September 30, 2023 | -$0.19 | +17.4% | +52.5% |
| June 30, 2023 | -$0.40 | -25.0% | -42.9% |
- BIOCRYST PHARMACEUTICALS INC showed an increase of +381.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, BIOCRYST PHARMACEUTICALS INC’s diluted eps has grown by 211.0% (from $1.09 per share (loss) to $1.21 per share).
- The most recent figure is from BIOCRYST PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: